Evolution of LIFE EMPORE project

The Life Empore project consists of 7 phases, spreaded out over a period of 36 months, which is the total duration of the project. At present, the LIFE EMPORE project is in its 4th stage. This phase focuses on the demonstration of the developed technologies.

Completed phases

The initial phases were dedicated to studying the problem of emerging pollutants at a European level and to the analysis on the presence of EC in the effluents in the European treatment plants. After having finished the first phases, the design phase and development of the pilot plant were next to be performed.

Current stage

At this moment, the LIFE EMPORE project is in Phase-Action 4 of Demonstration. This phase fosuses on the start-up of the pilot plant and monitoring the effectiveness of the developed technologies in eliminating emerging pollutants. During the start-up of the pilot plant, the automation of the demonstrator was carried out progressively. Due to the number of valves and processes involved in the removal of emerging contaminants, the demonstration began in manual mode.

In this current phase of the project, we are testing the different technologies that have been combined and grouped into levels. We are also analysing the elimination performance of a series of selected EC’s.

Eliminación de CE con LIFE EMPORE

Results

These are the results obtained in the period between July 5^th and October 31^st in 2018.

Elimination of prime concern substances

TRIFLURALIN, 4-T-OCTYLPHENOL, DEPH AND ISOPROTURON: Not detected
CHLORPIRIFÓS: Concentrations below its LOQ (<0.030 μg·L-1) and some specific days in August 2018, higher than the maximum admissible values of Directive 2013/39/EU.
DIURON: Concentrations detected below the threshold of the Directive 2013/39/UE (0.070 ± 0.018 μg·L-1).

Elimination of compounds 1st list observation

17-A-ETHINYLESTRADIOL AND 17-B-ESTRADIOL: Not detected (<LOD)
DICLOFENAC: Always detected; very variable concentration (μg·L-1):
- 18 (0.875 ± 1.102), Aug.18 (0.496 ± 0.049), Sep.18 (0.590 ± 0.163), Oct.18 (0.805 ± 0.176)
ERYTHROMYCIN: Detected in all samples; Concentration: 0.060 ± 0.015 μg·L-1

Elimination of another EC

ESTRIOL AND CHLORANPHENICOL: Not detected (<LOD).
ESTRONE: Detected some days (0.010-0.071 μg·L-1).
IBUPROFEN AND KETOPROFEN: Detected in July 2018 (0.133 ± 0.048 μg·L-1 and 0.098 ± 0.040 μg·L-1).

EMPORE (ref. LIFE15 ENV/ES/000598) is co-financied by LIFE+2015 Call, The LIFE Programme is the EU’s funding instrument for environment and climate action. The project is due to last 36 months, with a total budget of 1.783.824€.

previous next